By binding to the PD-1 receptor, nivolumab inhibits T-cell inhibition caused by cancer cells and their microenvironment, thereby restoring the immune response.[26] In CheckMate-026, 423 patients with untreated stage IV or recurrent NSCLC and a PD-L1 tumor-expression level of 1% or more were randomly assigned in a 1:1 ratio to receive nivolumab (3 mg/kg Q2W until PD or toxicity) or platinum-based chemotherapy (four to 6 cycles Q3W or until pemetrexed in non-squamous NSCLC (n = 46)) (Table 1). The gene discussed is CD274; the disease is cancer.